Compare EPAC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | ZLAB |
|---|---|---|
| Founded | 1910 | 2013 |
| Country | United States | China |
| Employees | 2100 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | EPAC | ZLAB |
|---|---|---|
| Price | $39.85 | $17.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $50.50 | ★ $57.22 |
| AVG Volume (30 Days) | 560.9K | ★ 1.0M |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $615,911,000.00 | $441,629,000.00 |
| Revenue This Year | $5.17 | $30.20 |
| Revenue Next Year | $5.97 | $34.71 |
| P/E Ratio | $23.23 | ★ N/A |
| Revenue Growth | 3.91 | ★ 24.14 |
| 52 Week Low | $35.01 | $16.82 |
| 52 Week High | $47.47 | $44.34 |
| Indicator | EPAC | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 28.16 |
| Support Level | $35.01 | $16.82 |
| Resistance Level | $41.73 | $18.29 |
| Average True Range (ATR) | 1.33 | 0.63 |
| MACD | 0.13 | 0.19 |
| Stochastic Oscillator | 71.28 | 19.26 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.